A Phase 2 Study of Durvalumab and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jun 2017 Planned End Date changed from 7 Jun 2019 to 31 Dec 2020.
- 14 Jun 2017 Planned primary completion date changed from 7 Jun 2019 to 31 Dec 2020.
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.